Cryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy

Tom Forda,b,⇑, Claire Wendena,b, Alison Mbekeani,a,b, Len Dallyd, Josephine H. Coxa, Merribeth Morine, Nicola Winstonea,b, Adrian V.S. Hillc, Jill Gilmoura,b, Katie J. Ewerce

a IAVI-HIL, Human Immunology Laboratory, International AIDS Vaccine Initiative, London, UK
b Department of Medicine, Imperial College, London, UK
c Centre for Clinical Vaccinology and Tropical Medicine and the Jenner Institute Laboratories, University of Oxford, UK
d EMMES Corporation, Rockville, MD, USA
e PATH Malaria Vaccine Initiative, Washington, DC, USA

Article info
Article history:
Received 16 September 2016
Received in revised form 31 January 2017
Accepted 18 February 2017
Available online 9 March 2017

Keywords:
Cryopreservation
Malaria
TRAP
CSP
ChAd63
MVA
PBMC

Abstract
Ex vivo functional immunoassays such as ELISpot and intracellular cytokine staining (ICS) by flow cytometry are crucial tools in vaccine development both in the identification of novel immunogenic targets and in the immunological assessment of samples from clinical trials. Cryopreservation and subsequent thawing of PBMCs via validated processes has become a mainstay of clinical trials due to processing restrictions inherent in the disparate location and capacity of trial centres, and also in the need to standardize biological assays at central testing facilities. Logistical and financial requirement to batch process samples from multiple study timepoints are also key. We used ELISpot and ICS assays to assess antigen-specific immunogenicity in blood samples taken from subjects enrolled in a phase II malaria heterologous prime-boost vaccine trial and showed that the freeze thaw process can result in a 3–5-fold reduction of malaria antigen-specific IFNγ-producing CD3+CD4+ effector populations from PBMC samples taken post vaccination. We have also demonstrated that peptide responsive CD8+ T cells are relatively unaffected, as well as CD4+ T cell populations that do not produce IFNγ. These findings contribute to a growing body of data that could be consolidated and synthesised as guidelines for clinical trials with the aim of increasing the efficiency of vaccine development pipelines.

1. Introduction

Functional immunological assays comprise a fundamental component of vaccine development and clinical trials [1,2]. ELISpot and intracellular cytokine staining by flow cytometry (ICS) are two laboratory techniques commonly used to assess the vaccine-induced immune responses both qualitative and quantitative, which contributes to understanding immunogenicity as well as vaccine potency and efficacy. These data influence go/no go decisions for the informed progression of vaccine development pipelines facilitating advancement from safety and immune correlate phase 1 vaccine trials [3,4]. In addition when used in epitope mapping studies the resultant data can also be fundamental to the development of novel vaccine candidates [5].

These assays are performed ex vivo therefore the inherent physical and temporal gap between blood draw and assay necessitates sample manipulations which, depending on circumstances of the study, have the potential to affect assay outcomes. It is for this reason that factors with the potential to create artefacts in immunogenicity data such as time from venepuncture to sample processing, shipping [6] and storage temperature [7] need to be anticipated and controlled so that decisions on vaccine development can be based on scientifically valid data. To this end the use of standardised, validated functional assays [8], stringent sample processing protocols, rigorous quality assurance [9] and reference laboratories working under strict regulatory frameworks such as Good Clinical Practice (GCP) [10] and Good Clinical Laboratory Practice (GCLP) [11] in vaccine development are increasingly important. These mechanisms help to ensure that data produced...
is as accurate a representation of in vivo immune function as possible and facilitate comparison of data across multiple studies. One key area of focus for clinical trials is the implementation of peripheral blood mononuclear cell (PBMC) cryopreservation for subsequent immunogenicity assessment [12]. Cryopreservation allows for lymphocytes to be stored long term so that assay runs can be consolidated for efficiency reasons (simultaneous analysis of multiple timepoints), so that samples can be distributed to multiple sites for assay development, validation and standardisation [13] and also so that samples can be shipped to laboratory sites that are remote from the clinical trial site. This is particularly useful when multiple trial sites are being used at distances that would prohibit the testing of samples within a time period that is acceptable to ensure that the functional potential of cellular samples remains intact. The use of central laboratories also serves to mitigate against the inherent variability in biological assays by reducing site to site variability thus enhancing precision and the maintenance of consistent quality control and assurance. This is particularly important given that important Go/No Go decisions may be based on immunogenicity data.

Opinion and empirical evidence characterising the effect of cryopreservation on T-cell function in clinical studies is divided and can be influenced by both vaccine strategy and specific historical models of local research infrastructure. To varying degrees cryopreservation has been implicated in both the stability of surface marker expression [14,15] and in reduced T-cell functionality [16]. A recent paper from Lemieux [17] demonstrated that whilst marker expression [14,15] and in reduced T-cell functionality reservation has been implicated in both the stability of surface can be influenced by both vaccine strategy and specific historical maintenance of consistent quality control and assurance. This is particularly important given that important Go/No Go decisions may be based on immunogenicity data.

One potential reason for the uncertainty regarding the importance of cryopreservation that in turn may result in variability in the integrity of response to stimulus from proteins of different origin.

The aim of this study was to decipher further the effect of cryopreservation on immunogenicity testing in order to prospectively inform planning for future clinical trials. We used IFNγ ELISpot and ICS assays to compare T-cell responses to malaria-specific antigens in a vaccinated population from PBMC samples processed directly from freshly drawn blood with PBMCs from the same blood draw that had been cryopreserved and subsequently thawed using validated methods and under GLP conditions. This work was carried out as a substudy to a larger clinical study assessing the efficacy of a combination malaria vaccine approach using the ChAd63 (prime) and MVA (boost) vectors encoding the antigens ME-TRAP, CSP and AMA1 [23].

2. Materials and methods

2.1. Samples

Samples were provided by the Jenner Institute at the University of Oxford as part of a Phase II/IIa Sporozoite multi-centre study (clinicaltrials.gov NCT01739036) being carried out at two clinical trial centres in Oxford and Southampton (United Kingdom). The study (VAC052) protocol was approved by the NHS Health Research Authority, National Research Ethics Service South Central Committee, UK. The study followed a prime-boost schedule assessing the efficacy of candidate combination malaria vaccine approaches using the ChAd63 (prime) and MVA (Boost) vectors encoding the antigens ME-TRAP, CSP and AMA1. In addition to the standard blood draw for primary immunogenicity assays as defined in the study objectives, supplemental Lithium–Heparin vacutainers were also drawn exclusively to carry out fresh vs cryopreserved/thawed PBMC comparisons. Samples from VAC052 vaccinees were compared at 3 time points; pre-immunisation (day 0), 7 days post-boost (day 63) and 1 day prior to controlled-human malaria infection (C-1), where this pre-challenge time point was scheduled on day 76 with a window of −4 and +3 days. Blood samples were couriered directly to the IAVI Human immunology laboratories (HIL) at Chelsea and Westminster Hospital, Imperial College, London and were processed within 8 hours of blood draw.

2.2. Sample processing

All processes for isolating, freezing and thawing cells, ELISpot and ICS were carried out according to validated standard operating procedures (SOPs) employed by the HIL and associated network of Clinical Research Centers against a framework defined by Good Clinical Laboratory Practice (GCLP) accreditation [9]. PBMC were isolated from whole blood samples at HIL using Ficoll gradient centrifugation. Upon isolation, PBMC were counted using a Vi-cell counter (Beckman Coulter) and re-suspended in R10 media (RPMI 1640). At this stage 55% of total PBMCs were frozen in freezing media containing 90% FCS and 10% DMSO. Freezing was carried out in a controlled stepwise manner using a rate control freezer and stored in vapour phase liquid nitrogen. The remaining 45% of PBMC were split to assess antigen specific cytokine secretion profiles by IFNγ ELISpot and ICS. Cryopreserved PBMC were thawed rapidly, washed and re-suspended in 5 mL R20 (R10 with 20% FBS) and incubated overnight in a humidified incubator at 37 °C with 5% CO2 in air. On the day of assay, cells were counted again (using Vi-cell counter, Beckman Coulter) and re-suspended in R10. Samples with viability of less than 80% following overnight incubation were excluded from analysis.
2.3. Peptides

Peptide pools covering *P. falciparum* circumsporozoite protein (CSP) and thrombospondin-related adhesive protein (TRAP) were kindly provided by the Jenner Institute [3]. Peptides were 20 amino acids (aa) long with overlap of 10 aa. Mega peptide pools with full protein coverage were provided alongside subpools representing smaller sections of the protein sequence. A hierarchy of peptide priority was used to assign pools to each sample as variable PBMC recovery and demands of two techniques meant that it was not always possible to stimulate cells with each peptide pool. Mega pools took priority over subpools and these subpools were themselves prioritised in order of expected magnitude of response. The mitogen Phytohaemagglutinin (PHA) was used as an assay control for ELISpot assays and *Staphylococcus Enterotoxin B* (SEB) for ICS in addition to Cytomegalovirus pp65 peptide pool that acted as a secondary positive control but also as a long-term memory recall peptide to compare responses with the short-term vaccine induced responses to CSP and TRAP.

2.4. ELISpot

Mabtech pre-coated IFNγ ELISpot 96-well plates were washed 3 times in 200 ml PBS (Sigma, Dorset, UK) per well prior to blocking with 200 μL R10 media (RPMI 1640) supplemented with 10% (v/v) heat-inactivated foetal bovine serum (FBS), 2 mM l-glutamine, 100 units penicillin, 0.1 mg/mL streptomycin, 10 mM HEPES buffer and 1 mM sodium pyruvate (all from Sigma) and incubated at 37 °C for at least 2 h. Blocking R10 media was decanted and 100 μL of peptide (1.5 mg/mL final concentration), PHA or mock (control-R10 media only) were added followed by 50 μL of fresh or thawed cells to give a density of 200,000 cells/well. Plates were incubated as above for 16–24 h.

Plates were subsequently washed manually, once with 200 μL PBS (Sigma, Dorset, UK) per well prior to blocking with 200 μL R10 media (RPMI 1640) supplemented with 10% (v/v) heat-inactivated foetal bovine serum (FBS), 2 mM l-glutamine, 100 units penicillin, 0.1 mg/mL streptomycin, 10 mM HEPES buffer and 1 mM sodium pyruvate (all from Sigma) and incubated at 37 °C for at least 2 h. Blocking R10 media was decanted and 100 μL of peptide (1.5 mg/mL final concentration), PHA or mock (control-R10 media only) were added followed by 50 μL of fresh or thawed cells to give a density of 200,000 cells/well. Plates were incubated as above for 16–24 h.

Plates and subpools from the same day were rarely mixed to ensure that the pre-defined populations were acquired or where mock IFNγ responses were above 0.2% of either parental population.

Table 1 Comparison of ELISpot responses. Mean SFU/million PBMC values are provided with 5th and 95th CI of the mean. P-values are for Wilcoxon-matched pairs signed rank test (two-tailed). Comparing fresh with post thaw response in each peptide pool/mitogen response and at each timepoint. Comparisons in bold are statistically significant. n indicates number of paired fresh/frozen datapoints analysed from individual samples.

| Antigen | ELISpot responses | Day 0 | Day 63 | C-1 (Day 76 –4/+3) |
|---------|------------------|-------|--------|--------------------|
| Mock    | sfu/10⁶ Fresh    | 15 (8, 21) | 22 (14, 30) | 21 (14, 27) |
|         | n                | 19    | 14     | 21                 |
| PHA     | sfu/10⁶ Fresh    | 281 (177, 385) | 1199 (876, 1522) | 845 (695, 995) |
|         | n                | 19    | 14     | 21                 |
| CMV     | sfu/10⁶ Frozen   | 110 (74, 294) | 149 (80, 378) | 327 (62, 592) |
|         | n                | 15    | 13     | 21                 |
| TRAP    | sfu/10⁶ Frozen   | 18 (9, 26) | 650 (491, 811) | 354 (170, 538) |
|         | n                | 19    | 14     | 11                 |
| CSP     | sfu/10⁶ Frozen   | 19 (1, 36) | 196 (98, 293) | 91 (68, 115) |
|         | n                | 16 (9, 23) | 27 (17, 38) | 34 (21, 47) |
|         | p                | 0.8999 | 0.0001 | 0.0010             |

Pre-freeze viability (%) | 97.7% (97.0, 98.5) | 98.1% (97.7, 98.5) | 95.3% (93.7, 97.0)
Post-thaw Viability (%)  | 97.5% (96.4, 98.5) | 97.6% (97.3, 98.7) | 97.5% (97.0, 98.5)
2.6. Analysis

Basic statistical analysis was performed on quality assured data using Prism version 6.0 by Graphpad. Confirmatory analysis was carried out by statistical consultants at the Emmes Corporation (Rockville, MD, USA) using SAS software (version 9.3). For ELISpot and ICS analysis background (mock) subtracted magnitudes of response (expressed as SFU /million PBMCs and % of parent population respectively) were generated for each sample – peptide stimulation combination. Where SFU values were negative after mock subtraction, a value of zero was assigned. Comparisons between fresh and thawed responses for each peptide were made on paired data using the Wilcoxon signed rank test (two-tailed). Paired data with missing values were excluded from analysis. Additional descriptive analysis was performed on flow cytometry data to investigate the effect of cryopreservation on polyfunctional cytokine profiles for cells expressing combinations of IFNγ, IL-2 and TNFα. A Boolean gating strategy was used to generate background subtracted, polyfunctional cytokine response data from the primary VAC052 ICS raw dataset. Analysis and presentation of distribution was performed using the SPICE analysis software package (version 5.3033) [25]. Comparison of fresh vs frozen distributions was performed using a student’s T-test. Data were not normalized and are presented as absolute values (% of total CD4+ or CD8+ T-cells with at least one cytokine response).

3. Results

3.1. Sampling efficiency

Whole blood samples from 28 unique sample IDs were couriered to the HIL over the duration of the study from two different study sites (Southampton and Oxford). The average time from blood draw to PBMC cryopreservation or fresh assay was 7.2 h (Southampton = 7.4 h, Oxford = 7.1 h). There was no significant difference between the processing times of samples from the two sites (p = 0.281). Mean cell viability for fresh samples post isolation across all time points was 98.0%, while for cryopreserved samples recovered viability was 96.8% and both averages fell within acceptability criteria according to validated protocols at HIL. Not all volunteers had samples at all time points and due to low cell recoveries decisions were taken according to planned criteria to leave out peptide pools with low expected immunogenicity. In addition, in order a minimum of two malaria specific peptides represented in stimulation panel alongside assay controls it was necessary to prioritise ELISpot over ICS. As the primary intent of this study was to compare the effect of cryopreservation on the responses to peptides matching 2 different vaccine inserts alongside a long-term recall antigen (CMV) the two most complete datasets for TRAP and CSP are presented here.

3.2. ELISpot – fresh vs. frozen

Data from the comparison of ELISpot responses to TRAP and CSP peptide pools obtained using freshly isolated and cryopreserved PBMC (Table 1 and Fig. 1) demonstrated an observable difference in vaccine-induced responses at both time-points post-immunisation, TRAP (P = 0.0001, D63 and P = 0.0010, C-1) and CSP (P = 0.0005, D63 and p < 0.0001, C-1). The negative effect on function was substantial in the TRAP responses where there was an average 73% (D63) to 59% (C-1) decrease in sfu from cells tested after cryopreservation. Although overall magnitude of responses to CSP were lower than to TRAP, responses were measurable in all post-vaccination samples when tested fresh. Post-cryopreservation reductions in CSP response, however, were greater than observed in TRAP, with an 86% (D63) and 63% (C-1) decrease in magnitude. 8% of CSP responses at D63 and 32% of responses at C-1 were indistinguishable from the mock (unstimulated) responses of the same sample. The mean magnitude for both antigens were also reduced at the later timepoint regardless of cryopreservation. This data is supported by the Bland Altman method comparison analysis (Fig. 2) which demonstrates the relationship between fresh and cryopreserved responses from individual samples showing that the degree of response reduction is largely proportional to the magnitude observed in fresh PBMCs and that there was an observable cryopreservation related reduction in all but one of the CSP-stimulated samples. A significant reduction in cytokine production post-thaw was also demonstrated in samples from both clinical sites when analysed separately and where sufficient data points provided meaningful analysis (not shown). As the mean processing time from each site was not significantly different this was not unexpected. The TRAP and CSP peptides, supplied by the Jenner Institute, were not previously qualified on the assay at HIL so no threshold of positivity was formally established in advance. For demonstrative purposes, an arbitrary positive
cut-off value was applied (based on previous peptide qualifications in the laboratory) (Fig. 3). Using this value, it was clear that the rates of positivity for TRAP responses were largely maintained in cryopreserved samples. However, against the CSP antigen, where mean observed responses for freshly isolated PBMC were 3–4 fold lower than TRAP responses at each time point, cryopreservation significantly reduced the frequency of “positive” responders against the demonstrative cut-off threshold.

In contrast to CSP and TRAP responses, CMV pp65 responses remained unaffected by the cryopreservation process at both D63 and C-1 time points indicating there was no impact of cryopreservation on the PBMCs capacity for IFNγ response to this antigen. IFNγ responses to the mitogen PHA at D63 and C-1 were increased 2-fold post-cryopreservation (p = 0.0001, D63 and p < 0.0001, C-1). This was not unexpected and has been previously attributed to a cryopreservation related reduction in suppressive cytokine production from monocytes [26]. Whilst the magnitude of PHA response in cryopreserved cells was consistent across each time-point the magnitude of fresh response at D0 was significantly lower than at the post vaccination timepoints. Unpublished data

Fig. 2. Bland–Altman plots showing relationship between fresh and frozen IFNγ ELISpot responses from individual samples. Mean SFU/million PBMCs of combined fresh and frozen data for each sample is plotted against the difference between the same data for each peptide. Data shown is for days 63 and C-1 (day 76 (−4/+3)) combined. Dashed line indicates mean difference for all samples. Dotted line in TRAP and CSP plots represents theoretical threshold where measurable magnitudes from fresh samples are reduced to zero in frozen samples. Reduction in magnitude of TRAP and CSP specific IFNγ response after cryopreservation increases proportionally with overall magnitude of fresh response.
from our lab shows that fresh PHA responses are more variable than frozen responses and the data presented here may indicate that activation status of volunteers may have an impact on suppression of response to this mitogen.

3.3. ICS – fresh vs. frozen

To further characterise the reduced function observed by ELISpot after cryopreservation at Day 63 and C-1, we analysed the Th1 cytokine profiles generated by flow cytometry in further detail for samples stimulated with the TRAP megapool (Fig. 4). TRAP was selected as responses were higher than to the CSP antigen and provided the greatest opportunity to observe any differences. Fig. 4 shows significant loss of IFN-γ (p = 0.001), IL-2 (p = 0.002) and TNFα (p = 0.001) expression in CD3+CD4+ cells after cryopreservation at the day 63 timepoint only. Furthermore, reduction in cytokine production is notable for being largely restricted to the CD3+CD4+ phenotype with less significant loss of IFNγ production in CD3+CD8+ cells at D63 only (P = 0.04). There was no observed reduction in both IL-2 and TNFα production from CD3+CD8+ cells at either timepoint. Polyfunctional analysis and presentation of TRAP-specific cytokine response distributions at Day 63 (Fig. 5) confirmed the overall cryopreservation-related reduction of mean IFNγ production in CD3+CD4+ cells. In these cryopreserved cells IFNγ contributed a smaller proportion of total analysed cytokine produced than in fresh cells of the same phenotype. Moreover, this analysis showed that loss of cells producing IFNγ was not just restricted to cells only producing this cytokine, there was also significant loss in the context of polyfunctional cells producing either or both IL-2 and TNFα.

4. Discussion

4.1. Loss of effector function

These data demonstrate a detrimental effect of cryopreservation on the functionality of malaria antigen-specific T cells on samples from a clinical trial where volunteers were immunised with heterologous viral vector regimes. The effect may be limited to a subset of short-term IFNγ-producing effector memory CD4+ T cells induced after the MVA boost whereas the CD4+ phenotype lacking IFNγ functionality, potentially central memory cells, are retained in cryopreserved PBMC. An observed reduction in response between day 63 and C-1 in fresh cells may also be indicative of a loss of these same weakly persistent effector memory cells in vivo at longer periods post-the MVA boost peak that would otherwise rely on IFNγ and persistence of circulating antigen for maintenance as described in natural infection[27].
One potential explanation for measurable reduction in Th1 cytokine response is from loss of total cellular material in the freeze–thaw process. Whilst some cellular loss is inevitable through the processes of cryopreservation, cell concentrations in assays are kept consistent and viability of cells after cryopreservation is maintained with the implementation of stringent, validated laboratory protocols. In addition, we have provided evidence here that the loss of cellular function is selective being only observed in the short-term vaccine responses rather than the longer held memory recall responses (CMV) and that the loss appears to be restricted to a specific cellular subset of CD4+ IFNγ producing effector memory T-cells. In an immunogenicity study of the heterologous prime-boost vaccination, Kimani et al. [3] showed that after ChAd63 priming, CD8+ T-cells are the most significant contributors of IFNγ when stimulated with TRAP peptides however after MVA boosting the contribution of IFNγ is more equally distributed between CD8+ and CD4+ T-cells. Given that the MVA boost appears to drive the activation of the CD4+ population it is perhaps likely that the reduction in CD4+ IFNγ production that we observe between fresh and frozen cells is indicative of a natural loss from a more highly differentiated and activated CD4+ effector memory cell subset predisposed to apoptosis that is driven by the MVA boost and that would be lost in the short term anyway – as seen in fresh analysis between D63 and C-1.

Where vaccine development and efficacy are concerned, the maintenance of functional memory is clearly an important consideration [28,29] so resolving the phenotype of those cells where function is lost post cryopreservation will be important. If through cryopreservation there is no significant loss in the function of cells responsible for the establishment of longer term memory then standardised freezing and thawing of PBMCs can still be considered as a valuable tool for vaccine trials.

Another potential reason for reduction in Th1 responses may be through loss of antigen presenting cell (APC) function or frequency. In such a scenario the specific T-cells could be retained however if there is reduced mechanism for presenting peptide in the context of MHC the functional capacity of the T-cells would be redundant. Although in this study we have not looked specifically for these APC populations the maintenance of long-term memory responses to CMV indicate that there is still a sufficient population of APCs to promote a response. In addition, the negative effect of cryopreservation on T cell function is less profound at the later timepoint presumably after a natural loss of less persistent effector cells indicating that there is likely to be more than sufficient APC capacity retained.

---

**Fig. 5. Analysis of polyfunctional cytokine response profile TRAP peptide megapool at Day 63 with respect to IFNγ TNFα and IL-2 production.** Graphs: all possible combinations of responses for the cytokines analysed are shown on the x-axis with the percentage of those distinct functional cell populations within either (a) CD3+CD4+ or (b) CD3+CD8+ responding cells shown on the y-axis. Bars correspond to mean percentages for each functional population. Crosses indicate significant differences between fresh and frozen frequencies for each functional cytokine combination obtained using students t-test. Piecharts: summarises the data by presenting mean frequencies of each functional population as a proportion of combined cytokine production. Segment colour matches the colour code for each cytokine combination on the x-axis of the graphs. Colour coded arcs indicate the mean proportion of total analysed cytokine production for IFNγ (red) TNFα (dark green) and IL-2 (light green). A significant reduction in the frequency of cytokine-producing T cells was observed in the CD4+, but not CD8+ T cell compartments. The greatest loss was within CD4+ T cells populations expressing IFNγ alone or in combination with either IL-2 or TNFα.
4.2. Implications for interpretation of correlates of protection

Given that the magnitude of cytokine response is variable between stimulation with different antigens there may be a risk that the inherent immunogenicity of different vaccines could be masked in cryopreserved samples. To demonstrate this in the context of the two malaria antigens used here, the magnitudes of responses are modelled against an arbitrary +ve/-ve threshold for positivity (Fig. 3). We found that although in comparison to data from fresh samples the magnitudes of TRAP responses are reduced post cryopreservation, the majority of these responses would still be categorised as positive. However, in the case of the responses to CSP, whilst data from assays performed on fresh samples would indicate that the vaccine was immunogenic, albeit with magnitudes lower than seen in TRAP responses, the data from thawed cells would indicate the contrary. In this case the interpretation of data from fresh and frozen cells stimulated with CSP would be quite different dependent on sample processing i.e. vaccine potency, or take rate, would have been underestimated using frozen samples only, and may have had significant implications Go /No Go decisions for vaccine development. As understanding of specific correlates of protection develops, the key desirable immunological indicators from clinical trials may become more defined which would have relevance to whether loss of function through cryopreservation is acceptable or not. To illustrate this point it is useful to consider the potential correlates of protection to the pre-erythrocytic stage of malaria because if, as previously demonstrated in both mouse [30] and humans [31] the induction of CD8+ T effector memory cells are essential for pre-erythrocytic protection against malaria, then the impact of cryopreservation may not be important as the flow cytometry data presented here indicates that this population is less likely to be affected.

Regardless of whether the utility of cryopreservation is assured, a factor that could be determined through study specific pilot analysis, the analysis of haematological samples that have been exposed to the least amount of processing and transportation as possible is still likely to provide the most comprehensive immunological insight and as accurate a proxy for in vivo function as possible [32]. Focus on the development of whole blood assays could contribute to reducing the influence of sample processing on immunological data from clinical trials however the reliance on established functional techniques and inherent issues with standardising cell counts in whole blood assays mean that efforts are largely restricted, certainly in flow cytometry, to phenotyping assays [33]. Efforts to reduce sample processing in the context of clinical trials can strengthen commitment to develop the capacity of trial sites where local immunology laboratories are a fundamental component, this is especially relevant in disease endemic countries where the vaccine target populations are those participating in trials. The feasibility of standardising functional assays [1] and implementation of effective quality assurance programmes across multiple sites [34] has been demonstrated particularly in the HIV vaccine field and such capacity certainly exists [35]. However additional insights into and justifications for working with fresh samples can only help to ensure that these centres are strengthened and procedures implemented to ensure and maintain quality and standardisation [2].

4.3. Future study

The scope of this sub-study was relatively small but provides some justification for follow up work that can address remaining questions about the effect of cryopreservation and in doing so complement existing frameworks for ensuring accuracy of immunological data where PBMCs are concerned. Areas to expand on include memory phenotyping of cells pre and post cryopreservation plus inclusion of markers for APC populations. The inclusion of other peptides pools from memory recall antigens in addition to vaccine specific peptides e.g. tetanus, candida, BCG should be considered. Finally, in addition to looking at the effect of cryopreservation on responses to heterologous prime-boost regimes to investigate whether specific T-cell induction and consequent loss was vector specific, it would also be useful to extend these studies to later time points to determine whether cryopreservation-related functional loss is still evident when persistence of vaccine-induced memory and protective efficacy are still indicated.

Acknowledgements

The work at the IAVI Human Immunology Laboratory, Imperial College was supported by a grant from PATH. Sample co-ordination at IAVI-HIL was carried out by John Brennan and Brendan McA-tarsney and project management support was provided by Lorna Clark. The VAC052 clinical trial was undertaken by the Jenner institute and sponsored by the University of Oxford. This trial was supported by the PATH Malaria Vaccine Initiative, the United Kingdom National Institute of Health Research through the Oxford Biomedical Research Centre (grant A91301, Adult Vaccine), and the Wellcome Trust (grants 084113/Z/07/Z and 45488/Z/05) to A.V.S.H. The clinical trial protocol was prepared by Adrian Hill and Nick Anag nostou. Clinical care and sample co-ordination was provided by Tommy Rampling, Ruth Payne, Eoghan de Barra, Hans de Graff, Raquel Lopez Ramon, Mary Smith, Norma Diaper, Adrienne Cook, Sharon Bevan, Natalie Lella, David Lloyd, and Ian Poulton. Project management was provided by Rachel Roberts and Alison Lawrie. Laboratory assistance was provided by Carly Bliss and Georgina Bowyer.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.vaccine.2017.02.038.

References

[1] Boaz MJ, Hayes P, Tarragona T, Seamos L, Cooper A, Birungi J, et al. Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin Vacc Immunol 2009:16:147–55. http://dx.doi.org/10.1128/CVI.00326-08.
[2] Njai HF, Gombe B, Khanshi T, Birungi J, Ruzagira E, Admassu D, et al. Setting up a standardized peripheral blood mononuclear cells processing laboratory to support multi-center HIV/AIDS vaccine and intervention trials. Labmedicine 2011;42:711–8. http://dx.doi.org/10.1309/Lm84wweusk4dab0t.
[3] Kimani D, Jagne YJ, Cox M, Kimani E, Bliss CM, Gitau E, et al. Translating the immunogenicity of prime-boost immunisation with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mol Ther 2014;22:1992–2003. http://dx.doi.org/10.1038/mi.2014.109.
[4] Sedegah M, Hollingdale MR, Farquoh F, Ganesan H, Belmonte M, Kim Y, et al. Sterile immunity to malaria after DNA prime/adeno virus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes. PLoS One 2014;9:e106241. http://dx.doi.org/10.1371/journal.pone.0106241.
[5] Hertz T, Ahmed H, Friedrich DP, Casmimo DR, Self SG, Corey L, et al. HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathog 2013;9: http://dx.doi.org/10.1371/journal.ppat.1003404.
[6] Bull M, Lee D, Stucky J, Chiu YL, Rubin A, Horton H, et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 2007;322:57–69. http://dx.doi.org/10.1016/j.jim.2007.02.003.
[7] Smith JC, Joseph HR, Green T, Field JA, Wooters M, Kaufhold RM, et al. Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vacc Immunol 2007;14:527–37. http://dx.doi.org/10.1128/CVI.00435-06.
[8] Russell ND, Hudgens MG, Ha R, Havenar-daughton C, Mcelrath MJ. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 2003;187:226–42. http://dx.doi.org/10.1086/367707.

[9] Gill DK, Levine GL, Ondondo B, Carter DK, Sato A, et al. Equivalence of responses as potential correlates of immunity. J Infect Dis 2003;187:226–42. http://dx.doi.org/10.1086/367707.

[10] Agency EM. Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples. London; 2012.

[11] Sarzotti-Kelsoe M, Cox J, Cleland N, Denny T, Needham L, et al. Value of a mixed vector immunization with recombinant adenovirus and MVA can protect rhesus blood mononuclear cells in a multicenter study. Clin Vacc Immunol 2013;20:590–5. http://dx.doi.org/10.1128/CVI.00693-12.

[12] Costantini A, Mancini S, Guiliodoro S, Butini L, Regnery CM, Silvestri G, et al. Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. J Immunol Methods 2014;409:107–16. http://dx.doi.org/10.1016/j.jim.2014.04.005.

[13] Owen RE, Sinclair E, Emu B, Heitman JW, Hirschkorn DF, Epling CL, et al. Evaluation and recommendations on good clinical practice guidelines for Phase I-II clinical trials. PLoS Med 2009;6:e1000067. http://dx.doi.org/10.1371/journal.pmed.1000067.

[14] Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 2014;22:464–75. http://dx.doi.org/10.1038/mt.2013.248.

[15] Russell ND, Hudgens MG, Ha R, Havenar-daughton C, Mcelrath MJ. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 2003;187:226–42. http://dx.doi.org/10.1086/367707.

[16] Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 2014;22:464–75. http://dx.doi.org/10.1038/mt.2013.248.

[17] Foulds KE, Wu CY, Seder RA. Th1 memory: implications for vaccine development. Immunol Rev 2006;211:58–66. http://dx.doi.org/10.1111/j.0903-2412.2005.00499.x.

[18] Costantini A, Mancini S, Guiliodoro S, Butini L, Regnery CM, Silvestri G, et al. Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. J Immunol Methods 2014;409:107–16. http://dx.doi.org/10.1016/j.jim.2014.04.005.

[19] Owen RE, Sinclair E, Emu B, Heitman JW, Hirschkorn DF, Epling CL, et al. Evaluation and recommendations on good clinical practice guidelines for Phase I-II clinical trials. PLoS Med 2009;6:e1000067. http://dx.doi.org/10.1371/journal.pmed.1000067.

[20] Venkataraman M. Effects of cryopreservation on immune responses. VIII effects of cryopreservation on immune responses. VIII conference on cell culture techniques and technologies for biopharmaceutical production. Biotechnol Adv 2000;18:139–46. http://dx.doi.org/10.1016/S0734-9751(00)00041-6.

[21] Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 2014;22:464–75. http://dx.doi.org/10.1038/mt.2013.248.

[22] Reyes-Sandoval A, Rollier CS, Milicic A, Bauza K, Cottingham MG, Tang C-K, et al. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antiadjuvant immunity. Mol Ther 2012;20:1633–47. http://dx.doi.org/10.1038/mt.2012.23.

[23] Aziz N, Margolick JB, Detels R, Rinaldo CR, Phair J, Jamieson BD, et al. Value of a mixed vector immunization with recombinant adenovirus and MVA can protect rhesus blood mononuclear cells in a multicenter study. Clin Vacc Immunol 2013;20:590–5. http://dx.doi.org/10.1128/CVI.00693-12.

[24] Costantini A, Mancini S, Guiliodoro S, Butini L, Regnery CM, Silvestri G, et al. Effects of cryopreservation on lymphocyte immunophenotype and function. J Immunol Methods 2003;278:145–55. http://dx.doi.org/10.1016/S0022-1759(03)00202-3.

[25] Owen RE, Sinclair E, Emu B, Heitman JW, Hirschkorn DF, Epling CL, et al. Loss of T cell responses following long-term cryopreservation. J Immunol Methods 2007;326:93–115. http://dx.doi.org/10.1016/j.jim.2007.07.012.

[26] Kircher CR, Dittrich MT, Guerov R, Boehm BO, Tary-Lehmann M. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods 2003;278:79–93. http://dx.doi.org/10.1016/S0022-1759(03)00226-6.

[27] Lemaux J, Jobin C, Simard C, Néron S. A global look into human T cell subsets following long-term cryopreservation. J Immunol Methods 2014;409:107–16. http://dx.doi.org/10.1016/j.jim.2014.04.005.

[28] Kj E, Ga OH, Cj D, Ka C, Sh S, Reyes-Sandoval A, et al. Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee. Nature 2013. http://dx.doi.org/10.1038/nature12985.

[29] Ahlers JD, Belyakov IM. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 2010;115:1678–89. http://dx.doi.org/10.1182/blood-2009-06-227546.

[30] Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic C, Forbes EK, Rollier CS, et al. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 2011;187:1347–57. http://dx.doi.org/10.4049/jimmunol.1100302.

[31] Hensley-McBain T, Heit A, De Rosa SC, McElrath MJ, Andersen-Nissen E. Protective CD8+ T effector memory T cell differentiation in chronic infection. Curr Immunol Rev 2013;9:190–206. http://dx.doi.org/10.2174/1573395509666131126231209.

[32] Bourguignon P, Clément F, Renaud F, Le Bras V, Koutsoukos M, Burny W, et al. Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naive HIV-1-infected patients. J Immunol Methods 2014;414:1–10. http://dx.doi.org/10.1016/j.jim.2014.03.024.

[33] Ahlers JD, Belyakov IM. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 2010;115:1678–89. http://dx.doi.org/10.1182/blood-2009-06-227546.

[34] Hensley-McBain T, Heit A, De Rosa SC, McElrath MJ, Andersen-Nissen E. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee. Nature 2013. http://dx.doi.org/10.1038/nature12985.

[35] Venkataraman M. Effects of cryopreservation on immune responses. VIII effects of cryopreservation on immune responses. VIII conference on cell culture techniques and technologies for biopharmaceutical production. Biotechnol Adv 2000;18:139–46. http://dx.doi.org/10.1016/S0734-9751(00)00041-6.